Compare HCA Health Inc (HCA) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs JPMorgan Chase & Co — how do they compare? HCA Health Inc trades at $373.29 (market cap $82.17B), while JPMorgan Chase & Co trades at $345.3 (market cap $900.78B). The key difference: JPMorgan Chase & Co is far larger — about 11× HCA Health Inc's market cap, and JPMorgan Chase & Co pays the higher dividend (1.77%). Which is the better fit depends on your goals.
| HCA | JPM | |
|---|---|---|
Market Cap | $82.17B | $900.78B |
Sector | Health | Financials |
52-Week High | $545.13 | $346.91 |
52-Week Low | $334.32 | $282.84 |
Enterprise Value | $131.08B | — |
Dividend Yield | 0.84% | 1.77% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $373.09, up 0.51% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 preliminary revenue above expectations but cut full-year profit guidance, causing recent stock pressure. Analyst consensus remains bullish with a $469.40 price target, though multiple law firms are investigating potential securities law violations following the guidance revision.
Investment outlook balances strong operational performance against near-term headwinds. The stock offers value with a 12.76 P/E ratio and consistent earnings beats, but faces risks from rising expenses, payer mix challenges, and ongoing legal investigations. Institutional sentiment remains positive despite technical weakness and recent guidance concerns.
JPMorgan Chase & Co. (JPM) trades at $345.23, up 1.21% on the day, with a bullish technical outlook and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside a consensus price target of $372.73, signal positive momentum. Revenue growth is robust, rising to $181.85B in 2025, though net income dipped slightly to $57.05B. The stock benefits from institutional accumulation and media focus on CEO Jamie Dimon's economic insights.
The outlook for JPM remains favorable, driven by earnings resilience and sector leadership, but risks include geopolitical tensions, cybersecurity threats, and volatile cash flows. With a moderate buy rating from analysts and a reasonable P/E of 14.52, the stock offers value, though investors should weigh macroeconomic headwinds against its solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
